Polypeptide Intermediate Synthesis for High-Purity Cyclic Peptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing physiologically active polypeptides, such as glucagon derivatives, face challenges in achieving high purity, suitable yield, and efficient mass production, often resulting in low purity and difficult final purification processes due to excessive impurity generation and heavy metal management.
Innovation Solution
A novel polypeptide intermediate and resin composite compound, represented by specific chemical formulas, are used in a method involving solid-phase peptide synthesis, including steps of swelling, deprotection, activation, coupling, and cyclization, to efficiently produce high-purity polypeptides by altering the cyclization process to occur after linear synthesis of up to 15mer, reducing impurity generation and simplifying final purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional peptide synthesis methods are used to produce physiologically active polypeptides, then the production process can be established, but the purity decreases and impurities increase as the peptide length increases
Solution Approach 1:
The polypeptide synthesis is divided into two separate stages: first synthesizing a core cyclic segment (cyclo(Glu-Lys-Arg-Ala-Lys)) with high purity, then coupling additional amino acid segments to both ends. This segmentation allows the critical cyclic structure to be formed with high precision before extension, preventing impurity accumulation that would occur in continuous linear synthesis of longer peptides.
Solution Approach 2:
The N-terminal and C-terminal amino acid sequences are pre-synthesized as separate protected segments before being coupled to the core cyclic polypeptide. This preliminary action allows for controlled synthesis and purification of each segment independently, ensuring high overall purity when assembled into the complete polypeptide structure.
2Productivity
If conventional peptide synthesis methods are used, then production can proceed, but the yield is insufficient for commercialization
Solution Approach 1:
By segmenting the synthesis into core cyclic segment formation followed by terminal segment coupling, each stage can be optimized for high yield. The core cyclic segment synthesis achieves high conversion efficiency, and the subsequent coupling reactions are designed to minimize material loss, collectively providing sufficient overall yield for commercial production requirements.
Solution Approach 2:
The synthesis parameters are optimized at each stage: the core cyclic segment synthesis uses specific coupling reagents and conditions to maximize yield, while the terminal coupling reactions use optimized ratios of reactants and controlled reaction times. These parameter optimizations ensure high overall yield suitable for commercialization.
3Adaptability or versatility
If peptide length increases in conventional synthesis, then more complex structures are achieved, but final purification becomes difficult
Solution Approach 1:
The segmented synthesis approach allows each segment to be synthesized and partially purified independently before assembly. The core cyclic segment is formed with high structural definition, and terminal segments are coupled in a controlled manner. This segmentation maintains manufacturing ease by breaking down the complex purification challenge into smaller, more manageable steps at each synthesis stage.
Solution Approach 2:
Different regions of the polypeptide are synthesized with different levels of protection and purification strategies tailored to their specific requirements. The core cyclic region, which requires high structural precision, receives focused purification attention, while terminal regions are synthesized with protective groups that facilitate selective purification. This local quality approach makes the overall purification process more manageable despite increased structural complexity.
Data Source
AI summary
The present invention relates to a novel intermediate used for physiologically active polypeptides and a method for preparing the same. The novel intermediate may be effectively used as an intermediate for the preparation of physiologically active polypeptide pharmaceuticals, and may be efficiently used for the preparation of high-quality pharmaceuticals by providing a polypeptide intermediate of high yield and high purity.